These free online tools let you skip the setup and start tracking your money right away. Many, or all, of the products featured on this page are from our advertising partners who compensate us ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...

How much should investors expect sales of Keytruda, the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with ...

This includes oral (by mouth), enteral (into the gastrointestinal tract), mucosal (through a mucus membrane), and percutaneous (through the skin). Administration routes are based on the medication ...

The waiver, announced by Secretary of State Marco Rubio, seemed to allow for the distribution of H.I.V. medications, but whether the waiver extended to preventive drugs or other services offered ...

Results have been announced from a Phase III trial of Merck & Co’s (NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s (TYO: 4523) orally available multiple ...

Two separate groups of medical experts and political advisers in Shanghai and Beijing are sounding the alarm over the country’s centralized drug procurement system and the drugs on a list of ...

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...

and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima ... Biotech-partnered TROP2 antibody-drug conjugate sac-TMT and the Moderna ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against its limits after racking up around 50 approvals since getting its first FDA ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...